We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Dalton Announces Manufacturing and Development Agreement with RLPC

News   Jul 16, 2015

 
Dalton Announces Manufacturing and Development Agreement with RLPC
 
 
Advertisement
 

RELATED ARTICLES

Personalized Cancer Vaccine Shows Early Efficacy in Patients With Diverse Tumor Types

News

Treatment with the neoantigen cancer vaccine PGV-001 following standard-of-care adjuvant therapy was well tolerated and demonstrated potential clinical benefit in patients with diverse tumor types according to a Phase 1 study. The findings were reported during the virtual AACR Annual Meeting 2021.

READ MORE

CREB1: A Potential Target for Treating Pancreatic Cancer

News

Preclinical research using cell lines, genetic mouse models and human pancreatic tumor tissue samples has identified the transcription factor CREB1 as a potential therapeutic target for the treatment of pancreatic cancer.

READ MORE

Tacking Treatment-Resistant Fungus With New Formulation of Existing Drugs

News

Researchers have discovered a formulation of existing medicines that can significantly reduce the presence of the fungus Candida auris on skin, controlling its spread and potentially keeping it from forming infections that have a high mortality rate.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cancer Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE